Decompensated cirrhosis is characterized by disturbed systemic and splanchnic hemodynamics. Bacterial translocation from the gut is considered the key driver in this process. Intestinal decontamination with rifaximin may improve hemodynamics. This double-blind, randomized, controlled trial (clinicaltrials.gov, NCT01769040) investigates the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones. We randomized 54 stable outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n 5 36) or placebo twice a day (n 5 18). Forty-five patients were male, mean age 56 years (68.4), average Child score 8.3 (61.3), and Model for End-Stage Liver Disease score 11.7 (63.9). Measurements of hepatic venous pressure gradient, cardiac output, and systemic vascular resistance were made at baseline and after 4 weeks. The glomerular filtration rate and plasma renin, noradrenaline, lipopolysaccharide binding protein, troponin T, and brain natriuretic peptide levels were measured. Rifaximin had no effect on hepatic venous pressure gradient, mean 16.8 6 3.8 mm Hg at baseline versus 16.6 6 5.3 mm Hg at follow-up, compared to the placebo, mean 16.4 6 4 mm Hg at baseline versus 16.3 6 4.4 mm Hg at follow-up, P 5 0.94. No effect was found on cardiac output, mean 6.9 6 1.7 L/min at baseline versus 6.9 6 2.3 L/min at follow-up, compared to placebo, mean 6.6 6 1.9 L/min at baseline compared to 6.5 62.1 L/min at follow-up, P 5 0.66. No effects on the glomerular filtration rate, P 5 0.14, or vasoactive hormones were found. Subgroup analyses on patients with increased lipopolysaccharide binding protein and systemic vascular resistance below the mean (1,011 dynes 3 s/cm 5 ) revealed no effect of rifaximin. Conclusion: Four weeks of treatment with rifaximin did not reduce the hepatic venous pressure gradient or improve systemic hemodynamics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration rate or levels of vasoactive hormones. (HEPATOLOGY 2017;65:592-603).
P ortal hypertension (PH) in cirrhosis is driven by two factors: a structural component, characterized by increased intrahepatic resistance due to the disruption of the vascular architecture and by infiltration of fibrosis in the liver parenchyma (1) ; the second component is dynamic and characterized by endothelial dysfunction in the sinusoidal endothelium and by abnormal contractile properties of the hepatic stellate cells, which are negatively affected by elevated levels of nitric oxides and endotoxins. (2, 3) Portal pressure is further aggravated by an increased splanchnic inflow due to vasodilatation. Secondarily, systemic vasodilatation develops, leading to a low central blood volume (CBV) and a further reduction in systemic vascular resistance (SVR), which leads to increased cardiac output (CO) and the characteristic hyperdynamic circulation. (4) (5) (6) (7) Patients with decompensated cirrhosis have increased inflammatory activity, which is hypothesized to be due to bacterial translocation from the gut. (8) (9) (10) The increased levels of circulating endotoxins and inflammatory cytokines are believed to have a major negative impact on the hyperdynamic circulation.
Impaired intestinal motility, bacterial overgrowth, and immune dysfunction in the gut are evident in the patient with cirrhosis. (13, 14) In controlled trials, intestinal decontamination with norfloxacin has been shown to be beneficial for inflammation, splanchnic hemodynamics, and clinical outcomes in patients with decompensated cirrhosis. (12, (15) (16) (17) Rifaximin-a (XIFAXAN; Norgine Denmark A/S, for Alfa Wassermann, Bologna, Italy) is a nonabsorbable antibiotic exerting a broad range of antimicrobial activity, altering the overall composition of the gut microbiota by favoring nonpathogenic bacterial species. (18) (19) (20) (21) Rifaximin is used for the prevention of hepatic encephalopathy (HE) and may also have beneficial effects on overt HE and survival. (22) Previous uncontrolled studies have suggested that rifaximin attenuates PH and improves systemic hemodynamics by modulating the levels of endotoxins and nitric oxides arising from the bacterial translocation in patients with decompensated cirrhosis. (23, 24) A casecontrol trial suggested a prolonged effect of rifaximin on the risk of complications to PH. (25) It has also been hypothesized that patients with cirrhosis may benefit from rifaximin as an add-on to nonselective betablockers in the treatment of PH. (26) The effects of rifaximin on splanchnic and systemic hemodynamics in decompensated cirrhosis have, to our knowledge, not been assessed in a randomized trial. The aim of this randomized, double-blind, placebocontrolled trial was to evaluate the effects of rifaximin on splanchnic and systemic hemodynamics and renal function in patients with cirrhosis and ascites.
Patients and Methods
This double-blind, randomized, and placebo- The trial protocol is available as Supporting Information.
OUTCOME MEASURES
The primary outcome measures were hepatic venous pressure gradient (HVPG), CO, and glomerular filtration rate (GFR). Secondary outcomes were mean arterial pressure, SVR, CBV, vasoactive biochemical markers, and reversal of minimal HE (MHE).
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria were diagnosis of cirrhosis verified by clinical, biochemical, and ultrasound findings; presence of clinical or ultrasound-verified ascites within the last 3 months; age between 18 and 80 years; and PH with an HVPG of 10 mm Hg or higher. Exclusion criteria were cardiac or respiratory failure, invasive cancer within the past 5 years, clinical or biochemical signs of infection, antibiotic treatment 14 days prior to inclusion, overt HE defined as HE grade 2-4 according to the West Haven criteria, kidney failure with serum creatinine above 200 lmol/L, transfusion-requiring bleeding within 1 week prior to inclusion, blood hemoglobin level below 5.5 mmol/L, continuous abuse of alcohol with symptoms of withdrawal, or expected survival of less than 3 months. All patients gave informed consent.
STUDY DESIGN
Patients were randomized in a 2:1 fashion using a computer-generated logarithm provided by our external data manager. Patients were identified by a single four-digit randomization number. All patients and personnel were blinded to the treatment. Study medication was packed according to the randomization list (supplied by the data manager) by the Hospital Pharmacy of the Capital Region of Denmark. The rifaximin group (n 5 36) received one tablet of 550 mg twice a day, and the placebo group (n 5 18) received one tablet of placebo twice a day. Rifaximin and placebo tablets were similar in color, size, shape, and packing. Decoding could only be performed by the sponsor and principal investigator in unison. Unblinding was performed 6 weeks after the last patient-last visit, when all data were registered in the database and the trial was closed by the GCP unit of Copenhagen University Hospital. The investigational program was performed prior to randomization and after 4 weeks of treatment. All authors had access to the study data and reviewed and approved the final manuscript.
METHODS
Clinical history data, demographic data on the etiology and complications to cirrhosis, and comorbidities as well as standard biochemistry data were collected. The assessments included a glucose breath test, assessment of the GFR, and a liver vein catheterization (LVC). On the day of inclusion, patients were screened for MHE with the continuous reaction time test, and the psychometric hepatic encephalopathy score (PHES) (27, 28) ; and standard lab tests and clinical history were recorded. The glucose breath test was performed in the initial 28 patients. After an overnight fast, including abstinence from tobacco and wholegrain products, patients were asked to drink 25 g of glucose diluted in water. Measures of hydrogen in the expiration were recorded, as described. (29) LVC was performed on the second day, in the morning after an overnight fast. In patients with tense ascites, paracentesis was performed the day before LVC. Guided by fluoroscopy, a balloon catheter was brought through the femoral vein to the hepatic venous system. HVPG was measured as a mean of repeated measurements in at least three different positions. CO was assessed by the indicator dilution technique, using 150 KBq of 125 I-labeled human serum albumin. (6, 30, 31) Right atrial pressure was measured in the same setting. SVR was calculated as SVR580 3
Mean arterial pressure -Right atrial pressure CO
. Plasma volume and CBV were derived from CO as described. (32) GFR was measured as plasma clearance by multiple sampling. One injection of 10 mL of isotonic saline with 4 MBq of the indicator 51 chrome-ethylene diamine tetraacetic acid was given readily after the LVC, while the patient was resting in bed. (33) A gamma-counter was used to assess the radioactivity of 51 chrome-ethylene diamine tetraacetic acid (PerkinElmer, New York, NY) in the blood, and clearance was assessed as the plasma concentration time curve and the area under the plasma indicator curve. Plasma clearance was derived from the ratio between the injected amount of indicator and the area under the indicator curve. (33, 34) Before infusing radioactive isotopes, 25 mL of blood was procured from the femoral artery for the analyses of arterial ammonia, renin, and vasoactive markers; all tubes were placed on ice immediately after sampling.
Renin levels were estimated with a commercially available immunoradiometric assay (DGR International, Inc., Hamburg Germany). The detection limit was 0.31 g/mL, and the intra-assay and interassay variation was 2%.
Brain natriuretic peptide and troponin T concentrations were measured using the standard biochemical test by ElektroChemiLuminescens (Roche Diagnostics A/S).
Noradrenaline and adrenaline were measured as the stable metabolites methoxy-noradrenaline and methoxy-adrenaline using a commercially available kit (Acquity UPLC IClass Xevo TQ-S; Waters Corporation, Milford, MA) with a lower detection limit of 0.1 nmol/L.
Lipopolysaccharide binding protein (LBP) was measured in ethylene diamine tetraacetic acid plasma with a commercially available, solid-phase enzymelinked immunosorbent assay (Vaiomer SAS, Toulouse, France). Protease activity was assessed by recording absorbance at 405 nm. The minimal detection limit was 3.5 lg/mL.
Patients were seen in the outpatient clinic after 14 days of treatment, where complications and side effects were registered, together with counting the residual tablets and handing out medicine for the next 14 days of treatment. After 4 weeks, patients were readmitted to the hospital for repetition of the investigational program.
STATISTICAL ANALYSIS
For sample size calculation, a type I error of 0.05 was chosen. Sample size calculations were performed for the primary outcomes HVPG and GFR (a mean HVPG of 18 mm Hg and a mean GFR of 69 mL/ minute). (35, 36) Sample size calculation for CO was not performed. In a paired design, 48 patients completing the trial protocol were required to detect a 20% reduction in HVPG or a 20% increase in GFR, which we estimated were the smallest clinically relevant changes. With an expected 20% dropout rate, we planned to include 57 patients.
Intention-to-treat and per-protocol statistical analyses were planned. Differences between the two groups were assessed using the unpaired t testing of delta values (the difference between follow-up and baseline). Intestinal decontamination has been suggested to be more beneficial in patients with systemic vasodilation, (12) and we therefore performed post hoc analyses in the following subgroups: patients with low SVR, presence of MHE, activated LBP, or treatment with beta-blockers. Analyses of covariance (repeated measures), with Model for End-Stage Liver Disease (MELD) score, Child score, severity of ascites, white blood cells, SVR, PHES as a measure of MHE, and LBP as covariates, were performed. Data were handled using SAS statistical software (v9.4 and Enterprise v7.1; SAS Institute, Cary, NC) and GraphPad (Prism 6.0.7).
Results

PATIENTS
A total of 295 patients were assessed for eligibility (Fig. 1) . Fifty-four patients (45 men, 9 women) fulfilled the inclusion criteria and were randomized. Inclusion into the study was stopped in accordance with International Conference for Harmonization-GCP guidelines when 49 patients had completed the trial protocol; thus, the sample size was reached. (37) The majority of patients (94%) had ascites at the time of inclusion. At the time of screening (2-10 weeks prior), all patients had ascites, which was verified using puncture or ultrasound. Thirty-nine patients had tense or moderate ascites. Due to adjustments in diuretics, 3 patients had remitted their ascites; and another 6 had mobilized ascites that were only visible on ultrasound at the time of inclusion. Ten patients had refractory ascites. Six patients had tense ascites at both inclusion and follow-up and were relieved with paracentesis prior to LVC. Four patients were relieved with paracentesis within 1 week prior to inclusion. Forty-nine patients received diuretics in varying doses. Three patients did not tolerate diuretics due to previous episodes of hepatorenal syndrome, and 2 patients had stopped taking diuretics due to the side effects. All patients were kept on a stable dose of diuretics 1 week prior to and during the trial. The median age of the participants was 56 years (range 33-74), the median MELD score was 11 (range [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , and the median Child score was 8 (range 7-12). Alcohol was the predominant etiology (78% of patients). Ten patients had had an episode of overt HE prior to trial inclusion; 11 patients had bled from esophageal varices. Fifteen patients (10 rifaximin/5 placebo) were treated with concomitant beta-blockers (Table 1) . No hemodynamic or biochemical differences were detected between the two groups; patients in the rifaximin group had a higher MELD score, which probably reflects the higher number of Child C patients randomized to this group. Compliance with study treatment was 97.7%.
The first 28 patients who were included were assessed for small intestinal bacterial overgrowth with the glucose breath test. No patients had small intestinal bacterial overgrowth, and two of the 28 tests were invalid, most likely due to a lack of fasting and abstinence from tobacco before testing. Due to continuous negative testing, the assessment was abandoned as recommended by GCP guidelines. (37) PRIMARY ENDPOINTS
Hepatic and Systemic Hemodynamics
Rifaximin had no effect on HVPG (mean and standard deviation 16. (Fig. 2) . Similarly, no effect could be demonstrated on systemic hemodynamics as reflected by the CO, SVR (Fig. 2) , plasma volume, and CBV (Table 2 ; Supporting Fig. S2 ). Heart rate decreased in the rifaximin group (76 6 13 bpm at baseline versus 73 6 13 bpm at follow-up) compared to an increase in the placebo group (76 6 15 bpm at baseline versus 79 6 15 bpm at follow-up), P 5 0.034. A subgroup analysis of patients with SVR below the mean (1011 dynes 3 s/cm 5 , rifaximin n 5 24, placebo n 5 10) and patients treated with beta-blockers (rifaximin n 5 10, placebo n 5 5) did not reveal any effect of rifaximin on patients with disturbed vascular resistance. 
Kidney Function
Eight patients had signs of kidney failure, with a GFR below 60 mL/min. Twenty-two patients had clinically normal kidney function but decreased GFR between 60 and 90 mL/min. The remaining 24 patients had GFR above 90 mL/min. Renin levels were increased in 35 patients at baseline. The GFR and plasma renin were unaltered by the study treatment (Table 2) .
SECONDARY END POINTS Vasoactive Markers
Noradrenaline was unchanged by rifaximin (0. (Table 2) . Likewise, no changes were detected in adrenaline. Levels of pro-brain natriuretic peptide and troponin T were elevated in 27 (rifaximin 16, placebo 11) and 21 (rifaximin 13, placebo 8) patients, respectively. No changes were detected in pro-brain natriuretic peptide or troponin T ( Table 2) .
Levels of LBP significantly decreased in the rifaximin group, P 5 0.018 (Table 2) . LBP was activated to levels above 5.9 lg/mL in 37 patients (25 rifaximin, 12 placebo). The subgroup analysis on these patients with activated LBP at baseline did not show an effect of rifaximin on the primary outcomes (HVPG, 17 6 4 mm Hg at baseline versus 16.9 6 5.5 mm Hg at follow-up in the rifaximin group compared to 16.4 6 4.2 mm Hg at baseline versus 16.5 6 4.7 mm Hg at follow-up in the placebo group, P 5 0.86; CO, 6.6 6 1.7 L/min at baseline versus 6.8 6 2.2 L/min at follow-up in the rifaximin group compared to 7.3 6 1.9 L/min at baseline versus 7.1 6 2.3 L/min at follow-up in the placebo group, P 5 0.64; GFR, 85 6 26 mL/hour at baseline versus 84 6 32 mL/hour at follow-up in the rifaximin group compared to 94 6 28 mL/hour at baseline versus 84 6 21 mL/hour at follow-up in the placebo group, P 5 0.13). None of the secondary hemodynamic or vasoactive parameters or the MHE and ammonia levels were affected by rifaximin treatment in the subgroup analyses (data not shown).
Biochemistry
The standard biochemical measures were unaffected by rifaximin treatment (Supporting Table S1 ).
Hepatic Encephalopathy
As a measure of MHE, the continuous reaction time test improved significantly in the rifaximin group (1.711 6 0.74 at baseline versus 2.069 6 0.69 at Values are given as median and minimum to maximum as they do not follow normal distribution, unless otherwise stated. *One patient received 100 mg metoprololsuccinat daily. † One patient received 12.5 mg carvedilol daily.
follow-up) compared with the placebo group (1.647 6 0.7 at baseline versus 1.574 6 0.53 at follow-up). However, the PHES and arterial ammonia remained indifferent to rifaximin treatment ( Table 2 ). The subgroup analysis of patients with MHE, defined by a PHES below -4 (rifaximin n 5 22, placebo n 5 12), did not change the results (change in PHES, P 5 0.47; continuous reaction time test, P 5 0.053; and arterial ammonia, P 5 0.77). A repeated measures analysis of covariance, which was adjusted for time and Heart rate (bpm)
76 (12) 73 (13) -2.94 75.5 (15) 79 (15) 3.61 group, was performed on all outcomes with the MELD score, the Child score, the severity of ascites, LBP, white blood cells, SVR, and PHES as covariates. The results of the primary outcomes, HVPG, CO, and GFR, are stated in Supporting Table S2 . No changes in the overall results were found. All statistical exercises were repeated per protocol analyses. This did not change the results.
SAFETY
Three patients were withdrawn from the trial at days 1, 6, and 23 due to development of infections (Table 3) . One patient was diagnosed with hepatocellular carcinoma at day 18 and was withdrawn thereafter, and 1 patient completed the trial but refused a second LVC. Serious adverse events were registered in 5 cases (2 patients developed spontaneous bacterial peritonitis, 1 patient was diagnosed with duodenal ulcer, and 1 patient developed post-LVC infection in the inguinal region after the second LVC in the rifaximin group; 1 patient developed pneumonia in the placebo group); no patients presented with HE or variceal bleeding; and no patients died during the trial.
Discussion
The main findings after 4 weeks of treatment with rifaximin in patients with decompensated cirrhosis and ascites were as follows: no change in the HVPG, systemic hemodynamics, or renal function. We also did not find evidence to support an effect on systemic or arteriolar vasodilation. In this exploratory trial, the PHES as well as arterial ammonia were likewise unaffected by rifaximin.
Rifaximin may facilitate an overproduction of bacterial species that generate less oxidative stress, less nitric oxide production, and less amino acid production, which is hypothesized to explain the known beneficial effects of the drug in reducing recurrent HE. (22, 38) The present trial investigated the effects of rifaximin on systemic and splanchnic hemodynamics following the current hypothesis that bacterial translocation induces an inflammatory response, which again agitates the dysfunction of the hepatic stellate cells and the hyperdynamic circulation in cirrhosis. Using rifaximin for intestinal decontamination, this cascade of events is anticipated to be disrupted, facilitating an improvement in systemic hemodynamics. (39) This theory has previously been tested in a small uncontrolled study demonstrating a decrease in HVPG and an increase in CO and SVR in all of the 13 included patients after 4 weeks of rifaximin treatment. (23) Further, the interleukin-6 and tumor necrosis factor-a levels were also attenuated by treatment. Another uncontrolled study of 30 patients found a substantial effect of rifaximin on both the HVPG and endotoxin levels. (40) This study was followed by a case-control study, in which the cohort was matched to 46 controls, showing beneficial long-term effects of rifaximin on HVPG, survival, and complications of cirrhosis. (25) It is worth noting that only the 23 responders to treatment with rifaximin were rolled over into the case-controlled study, which may bias the results in favor of rifaximin. Additionally, the study provides no data on alcohol consumption or comorbidities in either group, facts that may indeed affect complication rates and cirrhosis survival. About half of the patients who were included in these two trials were Child C. There is a high risk of bias in these studies due to the nonrandomized designs, which imply a risk of false-positive results.
One may hypothesize that the possible effect of rifaximin is clearer in the more severely disturbed hemodynamic state; this effect may not be repeatable in a trial with only 20% of Child C patients, such as ours. The subgroup analysis (paired t test) on primary outcomes in Child C (9 patients) in the rifaximin group did not reveal a significant treatment effect. The majority of patients included in the present trial (85%) were hemodynamically disturbed, with SVR values below 1,200 dynes 3 s/cm 5 and a mean CO of 6.7 L/ minute. The subgroup analysis of patients with SVR values below average (1,011 dynes 3 s/cm 5 , n 5 34) and of patients with activated LBP (LBP values above 5.9 lg/mL, n 5 37) also did not demonstrate a beneficial effect of rifaximin. The results might differ markedly had we investigated the effects of rifaximin in the unstable patient recovering from acute-on-chronic liver failure or recent infection.
Some considerations about our trial methods need elaboration. Patients were treated for 4 weeks, allowing for a short but stable treatment period and a quick return to the hospital for reassessment. The treatment duration has varied a great deal in rifaximin trials, depending on the study aim, the patient categories, and the methods of assessment. (23, 25, 41) A longer treatment period may impact HVPG, but to date this has not been investigated.
A period of 3 years was required to enroll 54 stable patients in the present trial, with a screen failure ratio of 1:5.5. It can be argued that the 54 randomized patients were a highly selected group with no evidence of malignancy, acute or recent infection, or alcohol abuse, which are endemic conditions in chronic liver disease. This selection of patients may bias the results. Alcohol use was self-reported, and s-ethanol tests were not performed. An underreporting of alcohol use is possible in this patient group; however, no patients showed signs of active alcoholism or withdrawal symptoms during follow-up. Antibiotics are frequently used in patients with cirrhosis, and though we tried to avoid this, 1 patient received 3 days of penicillin for an asymptomatic urinary tract infection. One patient was infected with Clostridium difficile, and another patient tested positive for vancomycin-resistant Escherichia coli; both were asymptomatic throughout the study period and received no antibiotics during the 4 weeks. Treatment with beta-blockers may compromise the effects of rifaximin because a recent trial has suggested some effect of beta-blockers on gut microbiota. (42) Fifteen patients received beta-blockers, but the subgroup analysis revealed no difference between these groups. A recently published abstract explored the potential role of rifaximin as an addition to propranolol. (26) Seventeen patients received combination therapy, which led to a higher decrease in HVPG after 3 months of treatment. Rifaximin also reduced the efficient dose of propranolol to a mean of 127 mg/day. Further data from this and other studies may tell us more about the effects of combination therapy.
The strength of the trial is clearly the randomized design, with personnel, patients, and outcome assessors blinded to treatment until the results were ready for analysis. Compliance with medication and investigations was high, and withdrawal was less than expected. Likewise, concomitant medical treatment was stable, with no variation in benzodiazepines, pain relievers, diuretics, or beta-blockers during the study period. Variance between baseline and follow-up was low for virtually all outcomes, suggesting a robust finding, which will not be influenced by longer treatment duration or an increased number of patients.
We have investigated the circulatory parameters related to cirrhosis extensively, addressing both hepatic and cardiac measures of dysfunction. At the same time, we addressed the possible effects of decreasing the inflammatory response on renal and arteriolar function and vasodilation by assessing vasoactive marker concentrations in relation to rifaximin. At the organ level, the neuropsychiatric parameters did not reveal any change in MHE, nor did rifaximin give rise to improvement in kidney function. Overall, these consistent results rather clearly support the conclusion that rifaximin has no benefits on the hemodynamics in decompensated patients without signs of overt HE.
In conclusion, rifaximin is efficient for recurrent HE, and evidence may support its use in acute overt HE or MHE patients. (22, 38, 43) This study does not support the use of rifaximin outside this indication. Further studies within the area should focus on the pathophysiological mechanisms that form the basis of how rifaximin changes the outcomes for patients with HE and MHE and should focus on the mechanisms of preventing bacterial translocation from the gut.
